Table 2.

Tumour growth inhibition of niraparib in xenograft models

Dose of niraparib	Tumour growth inhibition (%)
	Subcutaneous tumours	Intracranial tumours
15 mg/kg	13	55
30 mg/kg	49	56
45 mg/kg	54	83